BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Butt AA, Ren Y, Puenpatom A, Arduino JM, Kumar R, Abou-Samra AB. HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES. Liver Int 2018;38:1411-7. [PMID: 29271562 DOI: 10.1111/liv.13672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Butt AA, Yan P, Aslam S, Abou-Samra AB, Sherman KE, Shaikh OS. Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES. Clin Infect Dis 2020;71:664-6. [PMID: 31840746 DOI: 10.1093/cid/ciz1097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Yokosuka O, Sarin SK, Omata M. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? Hepatol Int. 2019;13:103-109. [PMID: 30539517 DOI: 10.1007/s12072-018-9915-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
3 Alkadi MM, Abuhelaiqa EA, Elshirbeny MF, Hamdi AF, Fituri OM, Asim M, Alkaabi SR, Derbala MF, Jarman ME, Ashour AM, Nauman A, Al Maslamani YK, Butt AA, Al-Malki HA. Eradication of hepatitis C virus infection in kidney transplant recipients using direct-acting antiviral therapy: Qatar experience. Immun Inflamm Dis 2021;9:246-54. [PMID: 33264509 DOI: 10.1002/iid3.386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Hu TH, Su WW, Yang CC, Yang CC, Kuo WH, Chen YY, Yeh YH, Chen SS, Tsao YY, Chen KM, Yan SL, Lai JH, Yao CD, Lim CH, Jen HH, Yeh YP, Chen SL, Chen HH, Chen SC; Changhua Hepatitis C Elimination Task Force. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan. Am J Kidney Dis 2021:S0272-6386(21)00575-8. [PMID: 33940114 DOI: 10.1053/j.ajkd.2021.03.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Javanbakht M, Archer R, Klausner J. Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system. PLoS One 2020;15:e0241615. [PMID: 33147293 DOI: 10.1371/journal.pone.0241615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cheema SUR, Rehman MS, Hussain G, Cheema SS, Gilani N. Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial. BMC Nephrol 2019;20:438. [PMID: 31779583 DOI: 10.1186/s12882-019-1631-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]